Amorfix arranges private placement of up to $1-million

Amorfix Life Sciences (TSX:AMF) intends to complete, subject to regulatory approval, a non-brokered private placement of between approximately 2,222,222 units and 4,444,444 units at a price of 22.5 cents a unit for gross proceeds of $500,000 to $1 million. Each unit will consist of one common share of Amorfix and one common share purchase warrant, [...]

Amorfix produces high-affinity antibodies to DSEs

Amorfix Life Sciences (TSX:AMF), together with its partner, has produced high-affinity antibodies to prion protein disease-specific epitopes (DSEs), which bind preferentially to several cancer primary cells and tumour cell lines, but not normal cells. “This represents a significant milestone for our cancer therapeutic antibody program,” CEO Dr. Robert Gundel said in a statement. “The generation [...]

Amorfix detects beta-amyloid with A4 Alzheimer’s test

Amorfix Life Sciences (TSX:AMF) and partner Biotrofix have successfully detected the presence of collected beta-amyloid (Abeta) peptide in cerebral spinal fluid from transgenic mice using the Amorfix A4 test. “This is the first time the detection of aggregated Abeta has been achieved in CSF from any mouse model,” Amorfix associate director of R&D Louise Scrocchi [...]

Amorfix A4 data in peer-reviewed journal

A research article about data generated by Amorfix Life Sciences‘ (TSX:AMF) A4 test has been published in the Journal of Alzheimer’s Disease, confirming the validity of the assay in detecting aggregated Amyloid beta. A beta is a neuropathological marker of the “APP London” mouse model offered for preclinical in vivo drug testing by reMYND NV.  [...]

Amorfix licenses ALS treatment to Biogen Idec

Amorfix Life Sciences (TSX:AMF) has granted Biogen Idec (NASDAQ:BIIB) exclusive worldwide rights to its lead amyotrophic lateral sclerosis (ALS) monoclonal antibodies. Under the accord, Amorfix will receive an up-front payment of $1 million (U.S.) and is eligible to receive milestone payments and royalties on sales.  Amorfix will also retain all rights for vaccines and diagnostics. [...]

Amorfix and reMYND in A4 pact for AD

Amorfix Life Sciences (TSX:AMF) has signed a partnership agreement with reMYND NV of Belgium to offer the Amorfix A4 amyloid testing service to reMYND’s contract research clients.  ”This partnership is an important first step to accessing new clients as we build our Alzheimer’s disease services business,” Vigen Nazarian, VP of strategic alliances for Amorfix, said [...]